Table 5.

Appearance of first antibody in seropositive RA cases where both antibodies of interest were present in prediagnosis serum. P value for Wilcoxon signed-rank test.

Comparing AntibodiesNo. Cases, +/nMean Yrsp
Comparing anti-CCP2 to anti-CarP-FCSMean yrs of anti-CCP2 preceding anti-CarP-FCS
Anti-CCP2 preceded anti-CarP-FCS4/16 cases0.13
Anti-CarP-FCS preceded anti-CCP20/16 cases0.76
First appearance in same sample12/16 cases
Comparing anti-CCP2 to anti-CarP-FibMean yrs of anti-CCP2 preceding anti-CarP-Fib
Anti-CCP2 preceded anti-CarP-Fib4/12 cases0.13
Anti-CarP-Fib preceded anti-CCP20/12 cases1.01
First appearance in same sample8/12 cases
Comparing RF-Neph to anti-CarP-FCSMean yrs of anti-CarP-FCS preceding RF-Neph
RF-Neph preceded anti-CarP-FCS2/16 cases0.81
Anti-CarP-FCS preceded RF-Neph3/16 cases0.08
First appearance in same sample11/16 cases
Comparing RF-Neph to anti-CarP-FibMean yrs of anti-CarP-Fib preceding RF-Neph
RF-Neph preceded anti-CarP-Fib2/7 cases1.00
Anti-CarP-Fib preceded RF-Neph1/7 cases0.01
First appearance in same sample4/7 cases
  • RA: rheumatoid arthritis; anti-CCP2: anticyclic citrullinated peptide antibodies version 2; anti-CarP: anti-carbamylated protein; FCS: fetal calf serum; Fib: fibrinogen; RF: rheumatoid factor; Neph: nephelometry; +/n: n positive over the case/control group size.